Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
New England Journal of Medicine · 13.02.2025 · 392 (7) · 653-665
DOI: 10.1056/nejmoa2403991 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.02.2025. Verfasst von Jennifer A Chan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neuroendocrine Tumors, Pancreatic Neoplasms, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 175-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Exelixis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
- Wright Center of Innovation and the Imaging and Radiation Oncology Core, University of Cincinnati, Cincinnati.
- University of California, San Francisco, San Francisco.
- Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ.
- University of Hawaii Cancer Center, Honolulu.
ORCID-Profile: Amylou C Dueck, Jonathan R Strosberg
Förderung
- NCI NIH HHS
- National Cancer Institute
- Exelixis
Zitieren
APA
Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., Ou, F. S., Dueck, A. C., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T. R., Konda, B., Trikalinos, N. A., Tawfik, B., Raj, N., Shaheen, S., Vijayvergia, N., Dasari, A., …, & Meyerhardt, J. A. (2025). Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine, 392(7), 653-665. https://doi.org/10.1056/nejmoa2403991
Vancouver
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine. 2025;392(7):653-665. doi:10.1056/nejmoa2403991
BibTeX
@article{Chan2025,
author = {Chan, Jennifer A and Geyer, Susan and Zemla, Tyler and Knopp, Michael V and Behr, Spencer and Pulsipher, Sydney and Ou, Fang-Shu and Dueck, Amylou C and Acoba, Jared and Shergill, Ardaman and Wolin, Edward M and Halfdanarson, Thorvardur R and Konda, Bhavana and Trikalinos, Nikolaos A and Tawfik, Bernard and Raj, Nitya and Shaheen, Shagufta and Vijayvergia, Namrata and Dasari, Arvind and Strosberg, Jonathan R and Kohn, Elise C and Kulke, Matthew H and O'Reilly, Eileen M and Meyerhardt, Jeffrey A},
title = {Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {7},
pages = {653--665},
doi = {10.1056/nejmoa2403991}
}
EUVIMED